Genovis ABFRA:5GV +4.19%93 PB Ratio is 4.72 as of Jul. 06, 2026, which is 71% below its 10-year median of 16.22. GuruFocus rates FRA:5GV with a GF Score™ of 93/100 and a GF Value™ of €2.57. The stock has 3 warning signs investors should review. Among 1,230 Biotechnology companies, Genovis AB ranks worse than 68.46% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-06), Genovis AB's share price is €1.84. Genovis AB's Book Value per Share for the quarter that ended in Mar. 2026 was €0.39. Hence, Genovis AB's PB Ratio of today is 4.72.
The historical rank and industry rank for Genovis AB's PB Ratio or its related term are showing as below:
FRA:5GV'
s PB Ratio Range Over the Past 10 Years
Min: 3.94 Med: 16.22 Max: 58.76
Current: 4.87
During the past 13 years, Genovis AB's highest PB Ratio was 58.76. The lowest was 3.94. And the median was 16.22.
FRA:5GV's PB Ratio is ranked worse than 68.46% of 1230
companies
in the Biotechnology industry
Industry Median: 2.99
vs FRA:5GV: 4.87
During the past 12 months, Genovis AB's average Book Value Per Share Growth Rate was 18.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 28.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 26.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 38.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Genovis AB was 64.00% per year. The lowest was -42.20% per year. And the median was 22.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Genovis AB PB Ratio Related Terms
Genovis AB PB Ratio Historical Data
* Premium members only.
The historical data trend for Genovis AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Genovis AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genovis AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genovis AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Genovis AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Genovis AB's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Genovis AB (FRA:5GV) has a PB Ratio of 4.72 as of Jul. 06, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Genovis AB and its competitors. This is 71% below median its historical median of 16.22. Over the past decade, Genovis AB's PB Ratio has ranged from 3.94 to 58.76. According to the industry distribution chart, Genovis AB ranks #842 out of 1230 companies in the Biotechnology industry, placing it in the top 68.5%.
Is Genovis AB's PB Ratio too high?
Genovis AB's current PB Ratio of 4.72 is 71% below median its 10-year median of 16.22. Over the past 10 years, this metric has ranged from a low of 3.94 to a high of 58.76. The Biotechnology industry median PB Ratio is 2.99. Genovis AB's value of 4.72 is 57.9% above this industry median. Based on the distribution chart, Genovis AB ranks #842 out of 1230 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Genovis AB has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Genovis AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genovis AB ranks #842 out of 1230 companies for PB Ratio. This places Genovis AB in the lower half of its industry. The industry median PB Ratio is 2.99. Genovis AB's value of 4.72 is 57.9% above this benchmark. Historically, Genovis AB's own PB Ratio has ranged from 3.94 to 58.76 over the past decade. While the company's 10-year median is 16.22 vs. the industry median of 2.99, Genovis AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.99, based on 1,230 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genovis AB's current PB Ratio of 4.72 is 57.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Genovis AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genovis AB's current PB Ratio is 4.72, which is 71% below median its own 10-year median of 16.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovis AB stock overvalued right now?
Genovis AB (FRA:5GV) has a current PB Ratio of 4.72. The stock's GF Value™ is €2.57, compared to a current price of €1.84 — trading 28.4% below its estimated fair value. The current PB Ratio is 4.72, which is 71% below median its 10-year median of 16.22 and 57.9% above the Biotechnology industry median of 2.99. Genovis AB's overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Genovis AB (FRA:5GV), the current PB Ratio is 4.72 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genovis AB (FRA:5GV) Overvalued in 2026?
Based on GuruFocus' analysis, Genovis AB stock appears to be undervalued.
The current stock price of €1.84 is trading 28.4% below its estimated GF Value™ of €2.57.
Key valuation signals for FRA:5GV:
PB Ratio: 4.72 (71% below median its 10-year median of 16.22)
GF Value™: €2.57 vs. price of €1.84 (28.4% below fair value)
Industry Position: 57.9% above the Biotechnology median (#842 of 1230)
No single metric tells the full story. See the FRA:5GV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genovis AB offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Its enzyme products, known as SmartEnzymes, are used by scientists all over the world, and the product formats facilitate the development and quality control of biological drugs. Its products include Enzyme and Antibodies. Geographically, it operates in Sweden and Rest of the world.
93GF Score
Get the complete analysis for FRA:5GV
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5GV has been successfully added to your 
